CCR8 antibodies for therapeutic applications

US11427640B1 · kind B1 · utility

Assignee

• BAYER HEALTHCARE LLC · DE

Inventors

• Sandra BERNDT · Hohen Neuendorf, DE
• Katharina Filarsky · Düsseldorf, DE
• Sabine Hoff · Potsdam, DE
• Helge Roider · Hohen Neuendorf, DE
• Uwe Gritzan · Cologne, DE
• Christian Votsmeier · Cologne, DE
• Wiebke Maria Nadler · Langenfeld, DE
• Su-Yi Tseng · San Francisco, US

Key dates

• Filing date: Jun 25, 2021
• Grant date: Aug 30, 2022
• Expiry date: Jun 25, 2041

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N33/57492
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.